and molecules provide benefit redefining of diseases. with today. Good the thank delivering expression of aim cancer At are genes monogenic we patients to joining to medicines Naomi. for the and us everyone morning that with underserved profound you, control Thank power currently a of small the Syros, you
we towards made important this XXXX, progress goal. In
unfit RARA-positive data selective a patients. diagnosed in AML currently or cohort AML X Phase initiating a advance promising We presenting clinical SY-XXXX, continue program and lead in RARα trial trial to first-in-class agonist relapsed our RARA-positive newly a in refractory patients
on development select of SY-XXXX, in to with which CDKX now in trial CDKX patients tumors. continue and leadership X inhibitor inhibition build is selective Phase We solid our in our selective oral a potent highly prioritizing the
entered with to And our of development oral disease effort into collaboration aim that Blood functional the with Global accelerating these we medicines a and sickle expand cell with a diseases. thalassemia for could Therapeutics patients in beta cure provide of the novel
a accomplishments XXXX. we tremendous Together, as these enter foundation provide
in and continued in year We and expect the culminating by data fourth for execution marked this meaningful both readouts to Syros, clinical be XXXX important XXXX in quarter.
continue key a parallel, engine, targets proven therapeutic gene-control to In role regulatory discovery shedding has productive on molecules selective generating against transcriptional and intervention platform small revealing mechanisms we targets. light for in a which that disease, our enhance new play
a models. single Let me highly demonstrated to inhibitor potentially with a update regressions preclinical transformative XXXX. agent a targeted and CDKX today is difficult including that robust on as represents for a complete that activity, cancers. of begin It an XXXX oral treat antitumor have We approach range potent cancer in selective believe
any or patients January, patient to first alterations. Rb histology XXXX. of breast, pathway with escalation dose cancer trial X enroll In we solid harbor multicenter open lung with This tumors is dosed in that colorectal, our approximately the Phase ovarian or label trial expected XX advanced of
data gather while dose the to through opportunities have to doses trial us along cohorts at to possible, rapidly more certain move escalation way. the We as designed expand as giving
treatment with XXXX. focused most have we respond the trial patient are populations on to likely that Importantly, we believe to
were cancers are in preclinical below ovarian Rb and sustained deeper models dose, of pathway lung tumor types in activity XXXX responses studying has breast, doses we shown and alterations. with tolerated at the associated and the antitumor more substantial maximum
enriching of will signals we seeing activity. increase By populations chances early our these Phase patient of believe our clinical we in trial, X for
safety, expect data, additional mid-XXXX. We including PK PD escalation initial fourth clinical quarter report this dose of in to and data, the tolerability, activity data year and in
evaluate initiate Following XXXX to single dose activity multiple a escalation, expansion agent in plan cohorts we and to safety the therapies. other with and combination further both as antitumor of
Moving patients path with these proof combination to in believe relapsed positive, patients remain XXXX We report on to and an AML. of accelerated in year the could this RARA-positive market. broad XXXX, development RARA-positive to refractory concept or with combination risk azacitidine AML of we quarter we data believe potential potential track MDS. XXXX in has data If support on with in high fourth
expect newly patients. diagnosed to path the which think in for data not are XXXX combination quarter important in standard also report in AML determining diagnosed on chemotherapy, fourth we mature optimal candidates azacitidine newly forward We who is suitable the in patients with
for these Together, AML. hope well-tolerated people we therapies closer addressing data the us for will oral to significant with need bring
medicines evolving landscape to is new or not While with cured. face still coming disease grim is with a the the prognosis. AML disease being rapidly relapsed Patients market, refractory
only to limited subsets response. of Survival duration composite range in complete remains low XX% target with six rates limited less and therapies approved Recently months. of response patient the than XX%
More the otherwise important. combine elderly are diagnosed newly For agents ability half diagnosed chemotherapy unfit patients, care. particularly approaches or standard emerging and the of newly intensive with AML to for tolerability than of as of the combination are are and unfit patients therapy other
unfit patient newly of we improve population quality in outcomes in combination an offer in for a also azacitidine of combination the develop new XXXX AML very presented believe while these to subset in with this may identifiable readily data regimens providing is important patients, ASH Based option that on treatment patients. we sick at that life. the goal diagnosed The October
molecular independence, onset CR/CRI showed this all and data in rapid and rate, transfusion of of Our deep, with patients. evidence as a cytogenetic action profile. many a CRs tolerability durability as saw well which of high rates RARA-positive of high were of We early aggregate favorable
toward give relapse also RARA-positive look us we our Importantly, as for readouts refractory data these or patients. AML confidence data
platform While in pipeline investment our becoming is of vision stage support believe clinical gene integrated that to strategic to sustainable our to priority a ongoing a our advance biopharmaceutical is and control programs, fully building key critical robust firmly company. our we
at months, ASH finding of stemmed leadership blood globin our new the an gene validation In in quarter red fetal highlighted control thalassemia to an In in cells. gene healthy make as effort presented oral fourth in and in our identification in fetal disease sickle recent a turn and the data we off hemoglobin our was typically the is develop broader several on presentation presentations. at This and annual on NFIX meeting repressor. medicine which to to beta cell from oral birth turned December,
our and the medicines disease progress sickle we two the promise years commercialize discover, thalassemia entered this a for with collaboration to program, on approach starting cell of and since new Based December and develop GBT into patients. in this beta in
Importantly, and explore inducing our this multiple for our success. increasing chances fetal in accelerating collaboration of us allowed to efforts approaches hemoglobin, targets and parallel
shorten cardiac as repeats dystrophy symptoms. announced the is an monogenic most the with monogenic death In dominant we It can affects common as system January, well causes being X. by myotonic our organs caused gene. which disease autosomal of second the lifespan central nervous type DMPK and in nucleotide disease respiratory focused and is DMX program on
the regulatory to of our use case approach controlling our gene. gene goal alter developing platform off disease, the the gene, faulty of a our of the is aim molecule with turning sickle this in with expression mechanisms expression of elucidate a medicine As to that cell small DMPK to single the the in copy
CDKXX at the suggest such a Epigenetics inhibitor, selective We presents susceptibility increasing inhibition cancer Cancer were DNA from opportunities also distinct damage meeting that data transcriptional in XXXX therapeutic preclinical from pleased PARP results CDKX targeted such Keystone The new effects inhibition. as to that repair January inhibitor a has as therapies CDKX involved demonstrating of inhibitors. to selective in present different Symposia, CDKXX
Keystone, diseases field underscore presented serve of targets and and dependencies ability our platform’s data potential that presentations at the transcriptional effective treatment. cancer. address that potentially have platform control our our as identify vast These Also reach to our could genes leadership eluded team gene for new of drug in the essential to highlighting
patients. is and platform. look tremendous into The we an our medicines and currently made our confidence our transformative continuing with the forward progress provide excellence have with XXXX our a reinforce We this for foundation across program for Syros. of to testament execute built just a underserved our and is we growth, also They to deep with portfolio beginning to enduring people, pipeline Syros as company for XXXX, a that it
in With financial the that, the I will our review to year over fourth Joe XXXX. to call results quarter and full turn
